Entero Reports Q2 Revenue of ₹20.87 Billion, Up From ₹15.71 Billion YoY

Market snapshot: Entero Healthcare Solutions Limited reported a top-line expansion for Q2, generating total revenue of ₹2,087 crore compared to ₹1,571 crore in the corresponding quarter of the previous year. This performance highlights an increase of ≈32.85% YoY (derived: ₹2,087 crore vs ₹1,571 crore) in consolidated revenue.

Data Snapshot

• Q2 Revenue: ₹2,087 crore versus ₹1,571 crore in the prior-year period
• Q1 FY27 Revenue: ₹1,940.50 crore with net profit of ₹38.16 crore

What's Changed

• Q2 revenue reached ₹2,087 crore, expanding from ₹1,940.50 crore reported in Q1 FY27 and ₹1,571 crore in Q2 of the previous fiscal year.

Key Takeaways

• Revenue expanded to ₹2,087 crore, marking a growth of ≈32.85% YoY (derived: ₹2,087 crore vs ₹1,571 crore).
• Sequential top-line growth builds upon the ₹1,940.50 crore achieved in Q1 FY27.
• Execution across healthcare product distribution continues to drive scale for the organization.

SAHI Perspective

Entero Healthcare's top-line trajectory underlines structural growth in tech-enabled pharmaceutical supply chain distribution across India. Continued quarterly revenue growth signals expanding market share and distributor network integration.

Market Implications

Strong revenue performance supports constructive sentiment around healthcare supply chain consolidation. Investors will assess whether operating efficiency and margin delivery match the scale of revenue expansion.

Trading Signals

Market Bias: Bullish

Robust revenue increase of ≈32.85% YoY (derived: ₹2,087 crore vs ₹1,571 crore) underlines sustained market share gains in healthcare distribution.

Overweight: Healthcare Distribution, Pharma Supply Chain

Trigger Factors:

• Operating margin performance in full Q2 detailed filings
• Working capital and inventory turnover metrics

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian pharmaceutical distribution sector is transitioning from fragmented regional trade channels toward organized, technology-backed distribution networks capable of delivering broad geographic reach and working capital scale.

Key Risks to Watch

• Working capital pressures associated with rapid revenue expansion across retail pharmacy networks.
• Integration risks related to ongoing acquisitions of regional pharmaceutical distributors.

Recent Developments

Entero Healthcare scheduled its Q2 FY27 board meeting for November 4, 2026, and previously reported Q1 FY27 total revenue of ₹1,940.50 crore with a net profit of ₹38.16 crore.

Closing Insight

Sustained revenue expansion of ≈32.85% YoY (derived: ₹2,087 crore vs ₹1,571 crore) positions Entero Healthcare strongly as healthcare distribution consolidation accelerates.

High Performance Trading with SAHI.